Insider sales are quantitatively insignificant relative to market cap (0.03%) and partly tied to option exercises/vesting, but the cluster's proximity to a revenue-miss earnings release warrants monitoring for additional sales in coming weeks. Watch for any 8-K filings regarding Tyvaso competitive dynamics or ralinepag NDA updates.
Price Chart
Executive Summary
United Therapeutics CEO Martine Rothblatt and EVP Paul Mahon collectively sold ~$490K in open-market shares within two days of the company's Q2 2026 earnings release, which showed a 2% YoY revenue miss ($783.3M vs. $804.6M consensus) but an EPS beat ($7.27 vs. $6.86). The sales follow option exercises and represent a small fraction of market cap, but the timing—right after a mixed earnings report with declining Tyvaso sales—raises watchfulness.
Key Financial Metrics
Key Facts
- CEO Rothblatt sold 4,895 open-market shares on Aug 5, 2026, for ~$2.5M (including sales after option exercises).
- EVP Mahon sold 8,300 open-market shares on Aug 6, 2026, for ~$4.3M (including sales after option exercises).
- Total open-market sales in cluster: ~$6.8M, representing 0.03% of $22.6B market cap—trivial proportionally.
- Q2 2026 revenue of $783.3M missed consensus by ~2.7% (down 2% YoY); EPS of $7.27 beat by 5.9%.
- Tyvaso Nebulized sales fell 18% YoY, partially offset by Tyvaso DPI growth.
- Insider cluster closed within 2 days of earnings, triggering AMPLIFIER cross-filing actuarial verdict (cluster-earnings-context + cluster-insider-trades).
Financial Impact
Total open-market insider sales of ~$6.8M (0.03% of market cap) are trivial in size; primary economic event is the mixed Q2 earnings with revenue miss but EPS beat.
Risk Factors
- Continued erosion of Tyvaso Nebulized sales could pressure top-line growth; Tyvaso DPI must accelerate to offset.
- Insiders selling after earnings may signal lack of confidence in near-term pipeline catalysts (ralinepag, IPF filing).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1786082523840 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $571.38 (+14.20%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $571.38 (+14.94%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $571.38 (+13.40%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $571.38 (+12.74%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $571.38 (+17.18%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $571.38 (+17.05%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $571.38 (+10.85%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $571.38 (+8.23%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access